on Marinomed Biotech AG
Marinomed Biotech AG Completes Restructuring Proceedings
Marinomed Biotech AG has successfully concluded its restructuring proceedings, as confirmed by the Korneuburg regional court. The process, initiated in August 2024, required achieving key milestones, including unanimous creditor approval of the restructuring plan and securing necessary funds. With these criteria met, the Management Board regains control from the insolvency administrator.
The restructuring plan includes a 30% creditor quota, payable over two years. A crucial element is the sale of the Carragelose business to Unither Pharmaceuticals, with shareholder consent obtained during a December meeting. CEO Andreas Grassauer emphasizes the need to develop new strategies while advancing Marinosolv and Solv4U commercialization.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Marinomed Biotech AG news